Company Filing History:
Years Active: 2025
Title: Per Hjerrild: Innovator in Cancer Treatment
Introduction
Per Hjerrild is a notable inventor based in Aarhus C, Denmark. He has made significant contributions to the field of cancer treatment through his innovative research and development of macrocyclic compounds. His work focuses on addressing the challenges posed by hypoxic cancer cells, which are often resistant to conventional therapies.
Latest Patents
Per Hjerrild holds a patent for "Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers." This patent describes macrocyclic compounds that include a 4-amido-2,4-pentadienoate (APD) moiety. The compounds are designed to exhibit selective toxicity to the hypoxic micro-environments commonly found in cancerous tissues. This innovative approach makes the disclosed compounds suitable for the treatment of hypoxic cancer cells.
Career Highlights
Per Hjerrild is affiliated with Aarhus Universitet, where he continues to advance his research in cancer treatment. His work has garnered attention for its potential to improve therapeutic outcomes for patients suffering from hypoxic cancers. With a focus on developing targeted therapies, he is contributing to the evolution of cancer treatment methodologies.
Collaborations
Per Hjerrild collaborates with esteemed colleagues, including Thomas Bjørnskov Poulsen and Kristian Mark Jacobsen. These partnerships enhance the research efforts and foster a collaborative environment for innovation in cancer treatment.
Conclusion
Per Hjerrild's contributions to the field of cancer treatment through his innovative patent and collaborative efforts highlight his commitment to advancing medical science. His work represents a significant step forward in the fight against cancer, particularly in targeting hypoxic cancer cells.